Genetic polymorphism of pharmacogenomic VIP variants in the Deng people from the Himalayas in Southeast Tibet

References

• Arabi A, Zahed L, Mahfoud Z, et al. (2009). Vitamin D receptor gene polymorphisms modulate the skeletal response to vitamin D supplementation in healthy girls. Bone 45:1091–7
   PubMed Web of Science ®Google Scholar
• Baker AR, McDonnell DP, Hughes M, et al. (1988). Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci 85:3294–8
   PubMed Web of Science ®Google Scholar
• Excoffier L, Lischer HE. (2010). Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows. Mol Ecol Resour 10:564--7
   Google Scholar
• Frosst P, Blom HJ, Milos R, et al. (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111–13
   PubMed Web of Science ®Google Scholar
• Fuselli S, de Filippo C, Mona S, et al. (2010). Evolution of detoxifying systems: the role of environment and population history in shaping genetic diversity at human CYP2D6 locus. Pharmacogenet Genomics 20:485–99
   PubMed Web of Science ®Google Scholar
• Gabriel S, Ziaugra L, Tabbaa D. (2009). SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet Chapter 2:Unit 2 12
   PubMedGoogle Scholar
• Gibbs RA, Belmont JW, Hardenbol P, et al. (2003). The international HapMap project. Nature 426:789--96
   Google Scholar
• Grant DJ, Hoyo C, Akushevich L, et al. (2013). Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women. Gynecol Oncol 129:173–8
   PubMed Web of Science ®Google Scholar
• Hong K, Bjerregaard P, Gussak I, Brugada, R. (2005). Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol 16:394–6
   PubMed Web of Science ®Google Scholar
• Hubner RA, Muir KR, Liu JF, et al. (2008). Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence. Int J Cancer 123:586–93
   PubMed Web of Science ®Google Scholar
• Köstner K, Denzer N, Mueller CS, et al. (2009). The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 29:3511–36
   PubMed Web of Science ®Google Scholar
• Kalow W. (2006). Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J 6:162–5
   PubMed Web of Science ®Google Scholar
• Kalow W, Otton S, Kadar D, et al. (1980). Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals. Can J Physiol Pharmacol 58:1142--4
   Google Scholar
• Kang L, Li S, Gupta S, et al. (2010). Genetic structures of the Tibetans and the Deng people in the Himalayas viewed from autosomal STRs. J Hum Genet 55:270–7
   PubMed Web of Science ®Google Scholar
• Limaye N. (2013). Pharmacogenomics, theranostics and personalized medicine – the complexities of clinical trials: challenges in the developing world. Appl Transl Genomics 2:17–21
   PubMedGoogle Scholar
• Ll K. (2010). Genetic diversity study of the Tibetan populations. Foreign Med Sci (Sec Medgeography) 31:5–11
   Google Scholar
• Miyamoto K-I, Kesterson RA, Yamamoto H, et al. (1997). Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol 11:1165–79
   PubMed Web of Science ®Google Scholar
• Newton-Cheh C, Guo C-Y, Larson MG, et al. (2007). Common genetic variation in KCNH2 is associated with QT interval duration the Framingham heart study. Circulation 116:1128–36
   PubMed Web of Science ®Google Scholar
• Poon AH, Gong L, Brasch-Andersen C, et al. (2012). Very important pharmacogene summary for VDR. Pharmacogenet Genomics 22:758–63
   PubMed Web of Science ®Google Scholar
• Ramos E, Doumatey A, Elkahloun AG, et al. (2014). Pharmacogenomics, ancestry and clinical decision making for global populations. Pharmacogenomics J 14:217--22
   PubMed Web of Science ®Google Scholar
• Roden DM, Altman RB, Benowitz NL, et al. (2006). Pharmacogenomics: challenges and opportunities. Ann Intern Med 145:749–57
   PubMed Web of Science ®Google Scholar
• Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. (2011). Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PLoS One 6:e18507
   PubMed Web of Science ®Google Scholar
• Sangkuhl K, Berlin DS, Altman RB, Klein TE. (2008). PharmGKB: understanding the effects of individual genetic variants. Drug Metab Rev 40:539--51
   Google Scholar
• Schwab M, Schaeffeler E. (2012). Pharmacogenomics: a key component of personalized therapy. Genome Med 4:93
   PubMedGoogle Scholar
• Sim SC, Altman RB, Ingelman-Sundberg M. (2011). Databases in the area of pharmacogenetics. Hum Mutat 32:526–31
   PubMed Web of Science ®Google Scholar
• Takahashi H, Wilkinson GR, Nutescu EA, et al. (2006). Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16:101–10
   PubMed Web of Science ®Google Scholar
• Tester DJ, Will ML, Haglund CM, Ackerman MJ. (2005). Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm 2:507–17
   PubMed Web of Science ®Google Scholar
• Thirumaran RK, Lamba JK, Kim RB, et al. (2012). Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochem Pharmacol 84:104–12
   PubMed Web of Science ®Google Scholar
• Thomas RK, Baker AC, Debiasi RM, et al. (2007). High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347–51
   PubMed Web of Science ®Google Scholar
• Thorn CF, Klein TE, Altman RB. (2013). PharmGKB: the Pharmacogenomics Knowledge Base. Methods Mol Biol 1015:311–20
   PubMedGoogle Scholar
• Whirl-Carrillo M, McDonagh E, Hebert J, et al. (2012). Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Therapeut 92:414--17
   Google Scholar
• Xu W, Zhang H, Wang F, Wang H. (2013). Quantitative assessment of the association between MHTFR C677T (rs1801133, Ala222Val) polymorphism and susceptibility to bladder cancer. Diagn Pathol 8:95
   PubMed Web of Science ®Google Scholar
• Yang ZF, Cui HW, Hasi T, et al. (2010). Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China. Genet Mol Res 9:1844–51
   PubMed Web of Science ®Google Scholar
• Yen-Revollo JL, van Booven DJ, Peters EJ, et al. (2009). Influence of ethnicity on pharmacogenetic variation in the Ghanaian population. Pharmacogenomics J 9:373–9
   PubMed Web of Science ®Google Scholar
• Yunus Z, Liu L, Wang H, et al. (2013). Genetic polymorphisms of pharmacogenomic VIP variants in the Kyrgyz population from northwest China. Gene 529:88–93
   PubMed Web of Science ®Google Scholar
• Zand N, Tajik N, Moghaddam AS, Milanian I. (2007). Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol 34:102–5
   PubMed Web of Science ®Google Scholar
• Zhou B-S, Bu G-Y, Li M, et al. (2014). Tagging SNPs in the MTHFR gene and risk of ischemic stroke in a Chinese population. Int J Mol Sci 15:8931–40
   PubMed Web of Science ®Google Scholar